Previous FDA studies of same‐day hemolytic reactions and AKI associated with Ig (intravenous or subcutaneous; not restricted to patients with CIDP) suggested that GGL was not associated with differences in hemolysis and AKI risks as for other IVIGs [12, 13]. Here, GGT5 is linked to acute kidney injury.